好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effect of Applying Inclusion and Exclusion Criteria of Phase III Complement Inhibitor and FCRN Inhibitor Trials to Acetylcholine Receptor-positive Generalized Myasthenia Gravis Patients in Routine Clinical Care
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (11:45 AM-12:45 PM)
11-014
To analyze the eligibility of acetylcholine receptor antibody-positive generalized myasthenia gravis (AchR+ gMG) patients treated in routine care into the phase III clinical trial of newly approved complement and FCRN inhibitor therapies. 

Complement and FCRN inhibitor therapies have been approved by FDA for AChR+ve gMG. Clinical trials leading to the approval had strict inclusion and exclusion criterias.

This retrospective study included AChR+ve gMG patients with documented myasthenia gravis activities of daily living (MG-ADL) scores, seen in outpatient clinics between January 2021 to June 2023. Clinical information including MG history, concomitant treatment(s) and MG-ADL score was analyzed at each clinic visit to determine the eligibility of patients into the clinical trials.

 
A total of 67 patients had a total of 330 visits between January 2021 and June 2023.  60 out 67 (89.5%) patients at 315 out of 330 (95%) clinic visits did not meet the eligibility criteria for the clinical trials. MG-ADL >5 was the single most frequent criterion not fulfilled, followed by IVIG use within the last 4 weeks of clinic visit. At 75 out of 330 (22.5%) clinic visits where MG-ADL score was >5, prior use of complement inhibitor medication and IVIG use within the last 4 weeks of clinic visit were the reasons for not meeting the eligibility criteria.
The majority of AchR+ gMG patients treated in routine care would not have met clinical trials criteria for phase III complement inhibitor and FCRN inhibitor trials. Broader inclusion criteria would increase patient eligibility and contribute to a better generalizability of the results in clinical trials.
Authors/Disclosures
Nakul Katyal, MD (University of Kentucky)
PRESENTER 		Dr. Katyal has nothing to disclose.
Katherine M. Clifford, MD Dr. Clifford has nothing to disclose.
Martavius T. Lovall, MD (Stanford Healthcare) An immediate family member of Dr. Lovall has received personal compensation for serving as an employee of Sylllable .
Neelam Goyal, MD, FAAN (Stanford University) Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Goyal has received research support from Argenx.
Srikanth Muppidi, MD, FAAN Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for argenx. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB/Ra Pharma. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizont Pharma. Dr. Muppidi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for J & J pharma. Dr. Muppidi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dianthus Pharma. Dr. Muppidi has received publishing royalties from a publication relating to health care.